Table 1. The viability of several human cell lines is unaffected by MpL.

	Cell viability
Cell line	Non-treated cells (viability - %)	Treated cells: 0.2 μM (relative viability - %)	Treated cells: 1 μM (relative viability - %)	Treated cells: 5 μM (relative viability - %)
HeLa	100.00 ± 1.85	105.60 ± 5.34	105.51 ± 0.65	107.26 ± 8.42
SH-SY5Y	100.00 ± 7.41	110.10 ± 9.09	101.45 ± 5.13	104.44 ± 9.76
HepG2	100.00 ± 16.65	90.29 ± 5.85	122.42 ± 12.81	92.58 ± 24.54
MCF10A neoT	100.00 ± 5.23	87.36 ± 10.74	116.28 ± 19.28	112.43 ± 22.06
U937	100.00 ± 2.27	97.78 ± 10.51	100.51 ± 2.80	113.78 ± 3.30
Differentiated U937	100.00 ± 5.74	111.97 ± 4.75	116.34 ± 4.26	119.78 ± 7.40
NK-92	100.00 ± 18.53	97.44 ± 6.73	68.11 ± 11.57	86.42 ± 9.37
Jurkat	100.00 ± 8.98	92.93 ± 8.23	101.70 ± 6.52	104.73 ± 4.81

Cell viability of different cell lines as measured by the MTS assay shows no significant toxicity of lectin MpL at three different concentrations (0.2 μM, 1 μM and 5 μM).